XL888 inhibited cell proliferation also in melanoma cells with intrinsic and acquired resistance to BRAF inhibitors that were dependent on different mechanisms including either overexpression of cyclin D1, PDGFR-β or COT, or NRAS mutation [141]. The gene discussed is NRAS; the disease is melanoma.